A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo Controlled, Single And Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Rivipansel (pf 06460031) Following Subcutaneous Administration With Rhuph20 (pf 06744547) In Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 11 May 2016
Price : $35 *
At a glance
- Drugs Rivipansel (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 29 Apr 2016 Status changed from recruiting to completed.
- 04 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 Apr 2016, according to ClinicalTrials.gov record.
- 23 Dec 2015 Crossover assignment has been removed from the trial design as reported by ClinicalTrials.gov.